CONSORT flowchart. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

Time to stabilization in the vertical direction. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

The description of games. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

The description of balance training. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

(A) Classification of up-regulated DEGs based on GO; (B)Classification of down-regulated DEGs based on GO; (C) KEGG enrichment bubble map of up-regulated DEGs; (D) KEGG enrichment... by Bingshuo Shi (21485387)

IFA disarmed capsule-mediated immune evasion. by Tingting Wang (123983)

IFA reduced the capsular biosynthesis through altering bacterial metabolism. by Tingting Wang (123983)

IFA effectively reduced the production of <i>K</i>. <i>pneumoniae</i> capsule. by Tingting Wang (123983)

IFA reduced the virulence of hypervirulent <i>K</i>. <i>pneumoniae</i> in <i>G</i>. <i>mellonella</i> larvae. by Tingting Wang (123983)

IFA did not affect LPS-induced inflammation response. by Tingting Wang (123983)

IFA abrogated capsule-associated hypermucoviscosity phenotypes of hypervirulent <i>K</i>. <i>pneumoniae</i>. by Tingting Wang (123983)

IFA sensitized hypervirulent <i>K</i>. <i>pneumoniae</i> to complement-mediated killing by inhibiting capsule. by Tingting Wang (123983)

Vertebral cancellous tissueμCT parameters are not significantly affected by aging from 16 to 21 weeks, housing type, or microgravity. by Rukmani Cahill (20939813)

“…(G) μCT volumetric reconstructions of a representative sample from each group show a slight decrease in bone parameters from FL mice, which are not deemed significant by statistical testing.…”

IFA treatment facilitated host immune clearance of hypervirulent <i>K</i>. <i>pneumoniae</i> by targeting capsule. by Tingting Wang (123983)

IFA effectively limited bacterial dissemination and protected mice from lethal hypervirulent <i>K</i>. <i>pneumoniae</i> pneumonia. by Tingting Wang (123983)

Safranin O fast green staining results of cartilage tissue in different groups of rat PTOA (A: normal group, B: mild PTOA group, C: severe PTOA group). by Peng-fei Han (694841)

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”